Is LGVN or GOSS more profitable?

Gossamer Bio has a net margin of -235.00% compared to Longeveron's net margin of -1,977.59%. Gossamer Bio's return on equity of 0.00% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets Longeveron -1,977.59% -223.19% -150.20% Gossamer Bio -235.00% N/A -112.04%

Does the media favor LGVN or GOSS?

In the previous week, Gossamer Bio had 15 more articles in the media than Longeveron. MarketBeat recorded 19 mentions for Gossamer Bio and 4 mentions for Longeveron. Gossamer Bio's average media sentiment score of 0.29 beat Longeveron's score of -0.04 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Gossamer Bio 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CELU or LGVN?

Longeveron has a consensus target price of $80.00, suggesting a potential upside of 3,020.12%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than Celularity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CELU or LGVN more profitable?

Celularity has a net margin of -345.45% compared to Longeveron's net margin of -1,977.59%. Celularity's return on equity of 0.00% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% Longeveron -1,977.59% -223.19% -150.20%

Does the media favor CELU or LGVN?

In the previous week, Longeveron had 1 more articles in the media than Celularity. MarketBeat recorded 4 mentions for Longeveron and 3 mentions for Celularity. Celularity's average media sentiment score of 0.00 beat Longeveron's score of -0.04 indicating that Celularity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celularity 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Longeveron 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LGVN or QNCX?

In the previous week, Longeveron and Longeveron both had 4 articles in the media. Quince Therapeutics' average media sentiment score of 0.48 beat Longeveron's score of -0.04 indicating that Quince Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Quince Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LGVN or SGMO?

In the previous week, Longeveron had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 4 mentions for Longeveron and 1 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.40 beat Longeveron's score of -0.04 indicating that Sangamo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Sangamo Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BYSI or LGVN?

Longeveron has a consensus target price of $80.00, indicating a potential upside of 3,020.12%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BYSI or LGVN more profitable?

BeyondSpring has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. BeyondSpring's return on equity of 0.00% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -28.88% Longeveron -1,977.59% -223.19% -150.20%

Does the media favor BYSI or LGVN?

In the previous week, Longeveron had 3 more articles in the media than BeyondSpring. MarketBeat recorded 4 mentions for Longeveron and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 0.00 beat Longeveron's score of -0.04 indicating that BeyondSpring is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Longeveron 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Longeveron (LGVN) Competitors

$2.58 -0.02 (-0.58%)

As of 11:50 AM Eastern

Compare

LGVN vs. GOSS, CELU, QNCX, SGMO, and BYSI

Should you buy Longeveron stock or one of its competitors? Longeveron's main competitors and comparable companies include Gossamer Bio (GOSS), Celularity (CELU), Quince Therapeutics (QNCX), Sangamo Therapeutics (SGMO), and BeyondSpring (BYSI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Longeveron compare to Gossamer Bio?

Longeveron (NASDAQ:LGVN) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

10.0% of Longeveron shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 7.4% of Longeveron shares are owned by company insiders. Comparatively, 4.2% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Gossamer Bio has a net margin of -235.00% compared to Longeveron's net margin of -1,977.59%. Gossamer Bio's return on equity of 0.00% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,977.59%	-223.19%	-150.20%
Gossamer Bio	-235.00%	N/A	-112.04%

Longeveron has higher earnings, but lower revenue than Gossamer Bio. Longeveron is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	6.82	-$22.70M	-$9.90	N/A
Gossamer Bio	$48.47M	0.69	-$170.37M	-$56.00	N/A

Longeveron has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

In the previous week, Gossamer Bio had 15 more articles in the media than Longeveron. MarketBeat recorded 19 mentions for Gossamer Bio and 4 mentions for Longeveron. Gossamer Bio's average media sentiment score of 0.29 beat Longeveron's score of -0.04 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gossamer Bio	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Longeveron presently has a consensus target price of $80.00, suggesting a potential upside of 3,020.12%. Gossamer Bio has a consensus target price of $256.00, suggesting a potential upside of 2,149.36%. Given Longeveron's higher probable upside, equities research analysts plainly believe Longeveron is more favorable than Gossamer Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Summary

Gossamer Bio beats Longeveron on 11 of the 16 factors compared between the two stocks.

How does Longeveron compare to Celularity?

Celularity (NASDAQ:CELU) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

19.0% of Celularity shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 7.4% of Longeveron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Longeveron has lower revenue, but higher earnings than Celularity. Celularity is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.41	-$91.72M	-$3.33	N/A
Longeveron	$1.20M	6.82	-$22.70M	-$9.90	N/A

Longeveron has a consensus target price of $80.00, suggesting a potential upside of 3,020.12%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Longeveron had 1 more articles in the media than Celularity. MarketBeat recorded 4 mentions for Longeveron and 3 mentions for Celularity. Celularity's average media sentiment score of 0.00 beat Longeveron's score of -0.04 indicating that Celularity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Longeveron	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celularity has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Celularity has a net margin of -345.45% compared to Longeveron's net margin of -1,977.59%. Celularity's return on equity of 0.00% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Longeveron	-1,977.59%	-223.19%	-150.20%

Summary

Celularity beats Longeveron on 9 of the 16 factors compared between the two stocks.

How does Longeveron compare to Quince Therapeutics?

Longeveron (NASDAQ:LGVN) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

Longeveron presently has a consensus price target of $80.00, suggesting a potential upside of 3,020.12%. Quince Therapeutics has a consensus price target of $206.71, suggesting a potential upside of 604.19%. Given Longeveron's higher probable upside, equities analysts clearly believe Longeveron is more favorable than Quince Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quince Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.62

In the previous week, Longeveron and Longeveron both had 4 articles in the media. Quince Therapeutics' average media sentiment score of 0.48 beat Longeveron's score of -0.04 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quince Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.0% of Longeveron shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 7.4% of Longeveron shares are held by insiders. Comparatively, 5.6% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Longeveron has higher revenue and earnings than Quince Therapeutics. Longeveron is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	6.82	-$22.70M	-$9.90	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A

Longeveron has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

Quince Therapeutics has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Quince Therapeutics' return on equity of 0.00% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,977.59%	-223.19%	-150.20%
Quince Therapeutics	N/A	N/A	-133.84%

Summary

Quince Therapeutics beats Longeveron on 10 of the 15 factors compared between the two stocks.

How does Longeveron compare to Sangamo Therapeutics?

Longeveron (NASDAQ:LGVN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

In the previous week, Longeveron had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 4 mentions for Longeveron and 1 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.40 beat Longeveron's score of -0.04 indicating that Sangamo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sangamo Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Longeveron presently has a consensus target price of $80.00, suggesting a potential upside of 3,020.12%. Sangamo Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Longeveron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Sangamo Therapeutics has a net margin of -310.81% compared to Longeveron's net margin of -1,977.59%. Longeveron's return on equity of -223.19% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,977.59%	-223.19%	-150.20%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Longeveron has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

Longeveron has higher earnings, but lower revenue than Sangamo Therapeutics. Longeveron is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	6.82	-$22.70M	-$9.90	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

10.0% of Longeveron shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 7.4% of Longeveron shares are held by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Sangamo Therapeutics beats Longeveron on 9 of the 15 factors compared between the two stocks.

How does Longeveron compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 7.4% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

BeyondSpring has higher earnings, but lower revenue than Longeveron. BeyondSpring is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	N/A	N/A	-$1.01M	-$0.12	N/A
Longeveron	$1.20M	6.82	-$22.70M	-$9.90	N/A

Longeveron has a consensus target price of $80.00, indicating a potential upside of 3,020.12%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BeyondSpring has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. BeyondSpring's return on equity of 0.00% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-28.88%
Longeveron	-1,977.59%	-223.19%	-150.20%

In the previous week, Longeveron had 3 more articles in the media than BeyondSpring. MarketBeat recorded 4 mentions for Longeveron and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 0.00 beat Longeveron's score of -0.04 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Longeveron	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeyondSpring has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market.

Summary

BeyondSpring beats Longeveron on 9 of the 15 factors compared between the two stocks.

Get Longeveron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGVN vs. The Competition

Export

Metric	Longeveron	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.18M	$3.91B	$7.27B	$13.03B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.26	14.13	274.95	25.63
Price / Sales	6.82	1,446.16	669.16	97.27
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	1.04	15.01	10.32	6.26
Net Income	-$22.70M	-$22.82M	$3.49B	$360.12M
7 Day Performance	-5.39%	-2.72%	-1.33%	-0.42%
1 Month Performance	-69.40%	-7.12%	-3.71%	-3.75%
1 Year Performance	-67.79%	29.24%	14.41%	4.84%

Longeveron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGVN Longeveron	1.9719 of 5 stars	$2.59 -0.6%	$80.00 +2,994.8%	-66.5%	$8.25M	$1.20M	N/A	38	Gap Down
GOSS Gossamer Bio	2.8696 of 5 stars	$11.69 +3.6%	$256.00 +2,089.9%	-95.5%	$34.25M	$48.47M	N/A	162	Trending News Analyst Revision Gap Down
CELU Celularity	0.2053 of 5 stars	$1.18 -4.8%	N/A	-47.2%	$34.16M	$26.55M	N/A	115
QNCX Quince Therapeutics	3.2611 of 5 stars	$31.35 +1.1%	$229.50 +632.1%	-90.6%	$31.98M	N/A	N/A	38	News Coverage Analyst Upgrade Gap Up
SGMO Sangamo Therapeutics	1.3261 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGVN) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Longeveron (LGVN) Competitors

LGVN vs. GOSS, CELU, QNCX, SGMO, and BYSI

How does Longeveron compare to Gossamer Bio?

Summary

How does Longeveron compare to Celularity?

Summary

How does Longeveron compare to Quince Therapeutics?

Summary

How does Longeveron compare to Sangamo Therapeutics?

Summary

How does Longeveron compare to BeyondSpring?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN vs. The Competition

Longeveron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Longeveron (LGVN) Competitors

LGVN vs. GOSS, CELU, QNCX, SGMO, and BYSI

How does Longeveron compare to Gossamer Bio?

Do insiders and institutionals have more ownership in LGVN or GOSS?

Is LGVN or GOSS more profitable?

Which has higher earnings & valuation, LGVN or GOSS?

Which has more volatility & risk, LGVN or GOSS?

Does the media favor LGVN or GOSS?

Do analysts recommend LGVN or GOSS?

Summary

How does Longeveron compare to Celularity?

Do institutionals and insiders have more ownership in CELU or LGVN?

Which has stronger earnings and valuation, CELU or LGVN?

Do analysts recommend CELU or LGVN?

Does the media favor CELU or LGVN?

Which has more risk & volatility, CELU or LGVN?

Is CELU or LGVN more profitable?

Summary

How does Longeveron compare to Quince Therapeutics?

Do analysts prefer LGVN or QNCX?

Does the media prefer LGVN or QNCX?

Do insiders & institutionals have more ownership in LGVN or QNCX?

Which has stronger earnings and valuation, LGVN or QNCX?

Which has more volatility & risk, LGVN or QNCX?

Is LGVN or QNCX more profitable?

Summary

How does Longeveron compare to Sangamo Therapeutics?

Does the media prefer LGVN or SGMO?

Do analysts prefer LGVN or SGMO?

Is LGVN or SGMO more profitable?

Which has more volatility & risk, LGVN or SGMO?

Which has stronger earnings & valuation, LGVN or SGMO?

Do insiders and institutionals have more ownership in LGVN or SGMO?

Summary

How does Longeveron compare to BeyondSpring?

Do insiders and institutionals believe in BYSI or LGVN?

Which has preferable valuation and earnings, BYSI or LGVN?

Do analysts rate BYSI or LGVN?

Is BYSI or LGVN more profitable?

Does the media favor BYSI or LGVN?

Which has more risk and volatility, BYSI or LGVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN vs. The Competition

Longeveron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools